0.02Open0.02Pre Close0 Volume5.63K Open Interest1.50Strike Price0.00Turnover966.96%IV230.43%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.1439Delta0.6115Gamma23.00Leverage Ratio-0.0142Theta0.0000Rho3.31Eff Leverage0.0001Vega
Sangamo Therapeutics Stock Discussion
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...
No comment yet